Barbara's Story: Navigating HER2+ MBC with Brain Metastases & Tucatinib-Based Treatment in the Second-Line Setting
Video Player is loading.
EP: 1.Treatment Selection and Sequencing in Third Line Settings and Beyond
EP: 2.Understanding Janet's Journey: Navigating HER2+ Metastatic Breast Cancer & Treatment Options
EP: 3.Exploring Third-Line Options in HER2+ mBC: Janet’s Case & Key Trial Insights from HER2CLIMB and EMILIA
EP: 4.Treatment Sequencing in HER2+ mBC: Real-World Data & Key Considerations in Third-Line Treatment Selection
EP: 5.Managing Oral Treatments and Patient Support Strategies in HER2+ mBC: Multidisciplinary Perspectives
Now Viewing
EP: 6.Barbara's Story: Navigating HER2+ MBC with Brain Metastases & Tucatinib-Based Treatment in the Second-Line Setting
EP: 7.Evolving Treatment Strategies in Early HER2+ Breast Cancer
This is an actor portrayal of a hypothetical patient profile developed for educational purposes based on characteristics of patients with multiple myeloma as seen in clinical practice. The hypothetical case was co-developed by staff Medical Writers with Cancer Network/ONN.
Recent Videos
Deciding Which RP to Utilize
Making Sense of PARP Inhibitors
Consideration for Other Androgen Receptor Inhibitors
Prostate Cancer in 2025
Clinical Pearls: Synthesizing Risk Assessment and Response Patterns in Advanced RCC Management
Auto-SCT or CAR T? A Case-Based Discussion in Relapsed DLBCL
Personalizing CAR T: Making the Right Call for Each Patient
Risk Score Stability and Post Lenvatinib Plus Pembrolizumab Treatment Selection in RCC
Future Directions and Key Insights in LBCL Treatment
Understanding PD-L1 CPS: Impact on Treatment Decisions in HER2+ Gastric Cancer
Related Content
